GELESIS HOLDINGS, IN

GLS
End-of-day quote. End-of-day quote  - 09/26
1.12USD +0.90%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Other Pharmaceuticals
Gelesis Holdings, Inc., formerly Capstar Special Purpose Acquisition Corp., is a commercial stage biotherapeutics company built for consumer engagement. The Company focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. It is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of FC.

Number of employees : 113 people.
Managers
Name Title
Yishai Zohar President, Chief Executive Officer & Director
Elliot Maltz Chief Financial Officer & Treasurer
Harry L. Leider Chief Medical Officer
Elaine Chiquette Chief Scientific Officer
David Pass Chief Operating & Commercial Officer
David Abraham Secretary & Chief Compliance Officer
Clayton Christopher Independent Director
Dominic Anthony Charles Perks Independent Director
Alison K. Bauerlein Independent Director
Paul R. Fonteyne Independent Director
Shareholders
Name Equities %
Puretech Health LLC 16,727,582 23.1%
HPSO SPV Ltd. 12,181,993 16.8%
SSD2 LLC 12,056,626 16.6%
Pacific Investment Management Co. LLC 5,657,607 7.81%
China Medical System Holdings Limited 4,501,770 6.21%
Yishai Zohar 1,426,014 1.97%
Aristeia Capital LLC 1,412,642 1.95%
Periscope Capital, Inc. 1,400,000 1.93%
Glazer Capital LLC 1,248,329 1.72%
Hudson Bay Capital Management LP 1,116,752 1.54%
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
GELESIS HOLDINGS, INC.-88.76%82
JOHNSON & JOHNSON-3.82%437 390
ELI LILLY AND COMPANY21.06%317 719
ROCHE HOLDING AG-14.15%273 173
ABBVIE INC.6.79%255 667
PFIZER, INC.-25.22%249 357
NOVO NORDISK A/S3.96%224 155
MERCK & CO., INC.13.05%219 838
ASTRAZENECA PLC14.46%167 902
NOVARTIS AG-6.80%166 661
BRISTOL-MYERS SQUIBB COMPANY15.01%153 866
AMGEN INC.1.53%123 558
SANOFI-12.12%95 184
GSK PLC-19.94%58 409
DAIICHI SANKYO CO., LTD.34.74%52 304
BAYER AG1.53%45 654
TAKEDA PHARMACEUTICAL COMPANY LIMITED18.55%39 954
CHUGAI PHARMACEUTICAL CO., LTD-6.83%39 636
JIANGSU HENGRUI MEDICINE CO., LTD.-31.04%29 648
ASTELLAS PHARMA INC.0.32%23 738
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-39.13%21 912
Brand Portfolio
More brands of Gelesis Holdings, Inc.